|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GALNT1 |
Gene summary for GALNT1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GALNT1 | Gene ID | 2589 |
| Gene name | polypeptide N-acetylgalactosaminyltransferase 1 | |
| Gene Alias | GALNAC-T1 | |
| Cytomap | 18q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | A0A024RC48 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2589 | GALNT1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.09e-13 | -5.10e-01 | 0.0155 |
| 2589 | GALNT1 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.18e-04 | 4.36e-01 | -0.1954 |
| 2589 | GALNT1 | HTA11_866_2000001011 | Human | Colorectum | AD | 1.89e-03 | -2.38e-01 | -0.1001 |
| 2589 | GALNT1 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.31e-05 | -4.23e-01 | 0.096 |
| 2589 | GALNT1 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.37e-03 | -4.08e-01 | 0.0338 |
| 2589 | GALNT1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.59e-02 | -3.28e-01 | 0.3859 |
| 2589 | GALNT1 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.82e-04 | -5.58e-01 | 0.2585 |
| 2589 | GALNT1 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.75e-13 | -5.14e-01 | 0.3005 |
| 2589 | GALNT1 | A015-C-203 | Human | Colorectum | FAP | 2.05e-18 | -3.38e-01 | -0.1294 |
| 2589 | GALNT1 | A014-C-040 | Human | Colorectum | FAP | 2.89e-02 | -1.89e-01 | -0.1184 |
| 2589 | GALNT1 | A002-C-201 | Human | Colorectum | FAP | 3.76e-11 | -2.82e-01 | 0.0324 |
| 2589 | GALNT1 | A002-C-203 | Human | Colorectum | FAP | 4.10e-03 | -1.57e-01 | 0.2786 |
| 2589 | GALNT1 | A001-C-108 | Human | Colorectum | FAP | 3.25e-12 | -9.16e-02 | -0.0272 |
| 2589 | GALNT1 | A002-C-205 | Human | Colorectum | FAP | 1.91e-15 | -3.47e-01 | -0.1236 |
| 2589 | GALNT1 | A015-C-005 | Human | Colorectum | FAP | 8.35e-03 | -2.11e-01 | -0.0336 |
| 2589 | GALNT1 | A015-C-006 | Human | Colorectum | FAP | 7.61e-11 | -2.16e-01 | -0.0994 |
| 2589 | GALNT1 | A015-C-106 | Human | Colorectum | FAP | 6.27e-08 | -1.78e-01 | -0.0511 |
| 2589 | GALNT1 | A002-C-114 | Human | Colorectum | FAP | 2.54e-14 | -2.92e-01 | -0.1561 |
| 2589 | GALNT1 | A015-C-104 | Human | Colorectum | FAP | 5.35e-24 | -3.86e-01 | -0.1899 |
| 2589 | GALNT1 | A001-C-014 | Human | Colorectum | FAP | 1.60e-06 | -1.19e-01 | 0.0135 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001821017 | Thyroid | PTC | peptidyl-threonine modification | 66/5968 | 125/18723 | 9.50e-07 | 1.43e-05 | 66 |
| GO:00190827 | Thyroid | PTC | viral protein processing | 18/5968 | 29/18723 | 7.83e-04 | 4.86e-03 | 18 |
| GO:00064866 | Thyroid | PTC | protein glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
| GO:00434136 | Thyroid | PTC | macromolecule glycosylation | 94/5968 | 226/18723 | 1.25e-03 | 7.13e-03 | 94 |
| GO:00700855 | Thyroid | PTC | glycosylation | 96/5968 | 240/18723 | 4.57e-03 | 2.15e-02 | 96 |
| GO:00091013 | Thyroid | PTC | glycoprotein biosynthetic process | 123/5968 | 317/18723 | 5.05e-03 | 2.33e-02 | 123 |
| GO:00091003 | Thyroid | PTC | glycoprotein metabolic process | 147/5968 | 387/18723 | 5.87e-03 | 2.64e-02 | 147 |
| GO:00072199 | Thyroid | PTC | Notch signaling pathway | 70/5968 | 172/18723 | 8.82e-03 | 3.67e-02 | 70 |
| GO:001603234 | Thyroid | ATC | viral process | 241/6293 | 415/18723 | 5.50e-25 | 2.04e-22 | 241 |
| GO:001908023 | Thyroid | ATC | viral gene expression | 64/6293 | 94/18723 | 8.44e-12 | 3.16e-10 | 64 |
| GO:001820917 | Thyroid | ATC | peptidyl-serine modification | 161/6293 | 338/18723 | 5.23e-08 | 9.44e-07 | 161 |
| GO:001821018 | Thyroid | ATC | peptidyl-threonine modification | 66/6293 | 125/18723 | 7.36e-06 | 7.56e-05 | 66 |
| GO:000721915 | Thyroid | ATC | Notch signaling pathway | 79/6293 | 172/18723 | 5.08e-04 | 2.96e-03 | 79 |
| GO:001908213 | Thyroid | ATC | viral protein processing | 18/6293 | 29/18723 | 1.58e-03 | 7.98e-03 | 18 |
| GO:000648612 | Thyroid | ATC | protein glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
| GO:004341312 | Thyroid | ATC | macromolecule glycosylation | 94/6293 | 226/18723 | 7.11e-03 | 2.82e-02 | 94 |
| GO:000910011 | Thyroid | ATC | glycoprotein metabolic process | 153/6293 | 387/18723 | 7.90e-03 | 3.06e-02 | 153 |
| GO:00085937 | Thyroid | ATC | regulation of Notch signaling pathway | 43/6293 | 95/18723 | 1.19e-02 | 4.22e-02 | 43 |
| Page: 1 2 3 4 5 6 7 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GALNT1 | SNV | Missense_Mutation | c.1566N>T | p.Gln522His | p.Q522H | Q10472 | protein_coding | tolerated(0.13) | benign(0.031) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| GALNT1 | SNV | Missense_Mutation | novel | c.96N>A | p.Asn32Lys | p.N32K | Q10472 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GALNT1 | SNV | Missense_Mutation | novel | c.320N>G | p.Lys107Arg | p.K107R | Q10472 | protein_coding | tolerated(0.65) | benign(0.003) | TCGA-AQ-A54O-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | adriamycin | CR |
| GALNT1 | SNV | Missense_Mutation | c.163C>T | p.His55Tyr | p.H55Y | Q10472 | protein_coding | tolerated(0.57) | benign(0) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GALNT1 | insertion | Nonsense_Mutation | novel | c.1017_1018insAACAGCTTTTAAAAACAAAAACTGATTGATTGTAAATTTTAAAT | p.Ser340AsnfsTer4 | p.S340Nfs*4 | Q10472 | protein_coding | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| GALNT1 | insertion | In_Frame_Ins | novel | c.94_95insAAATTT | p.Asn32delinsLysIleTyr | p.N32delinsKIY | Q10472 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GALNT1 | SNV | Missense_Mutation | novel | c.424N>T | p.Arg142Cys | p.R142C | Q10472 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A2M1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GALNT1 | SNV | Missense_Mutation | c.966N>C | p.Glu322Asp | p.E322D | Q10472 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| GALNT1 | SNV | Missense_Mutation | novel | c.1154C>A | p.Ser385Tyr | p.S385Y | Q10472 | protein_coding | tolerated(0.33) | benign(0.052) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GALNT1 | deletion | Frame_Shift_Del | c.113delA | p.Lys38ArgfsTer11 | p.K38Rfs*11 | Q10472 | protein_coding | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |